WELCOME to this Patient Advocacy organization's informational archive provided by MS Views and News
· Our live MS educational seminars average 72 people per educational program. SINCE our first program in February 2010, we have hosted more than 150 educational programs.
· Visit our Multiple Sclerosis Learning channel on YouTube archived by topic here: www.youtube.com/msviewsandnews
* Be Empowered with beneficial Multiple Sclerosis (MS) information - See our listings of upcoming Educational Programs --
Visit MS Views and News.org
View all the resources found on the left side of this blog. Use our 'search by topic' tool, when wanting to find specific information.
Monday, August 31, 2015
CLICK THE BANNER to find a program near you
For more information on Lemtrada click: https://www.lemtrada.com/
Sunday, August 30, 2015
Immunologist Prof Danny Altmann, from Imperial College London, said it may be too much to expect vitamin D to treat or reverse the effects of MS, but added the study supports the argument for additional supplements as a public health measure.
The authors feel that these findings warrant further investigation of the potential therapeutic benefits of vitamin D supplementation in preventing the onset and progression of MS.
Based on their findings, researchers concluded that “genetically lowered vitamin D levels are strongly associated with increased susceptibility to multiple sclerosis“.
Engineering students in India have developed an algorithm that can help detect multiple sclerosis at an early stage. MS is a chronic disease that destroys the protective sheath covering the nerves and can lead to difficulty in sight and the ability to move.
CLICK HERE to listen with this audio presentation
After the new page opens, click the diagram to begin the audio
Saturday, August 29, 2015
Demyelination by MS. The CD68 colored tissue shows several macrophages in the area of the lesion. Original scale 1:100. Credit: Marvin 101/Wikipedia
Patients with relapsing-remitting multiple sclerosis (RR-MS), the most common form of the disease, often have deficits in two neuropsychological functions, autobiographical memory (AM) and episodic future thinking (EFT), which impact quality of life. In a new study published in Restorative Neurology and Neuroscience, researchers report that training RR-MS patients in mental visual imagery (MVI) can improve AM/EFT functioning.
Thursday, August 27, 2015
This Peer Exchange is moderated by Paul Doghramji, MD, who is a family physician at Pottstown Memorial Medical Center in Pottstown, PA, and medical director of Health Services at Ursinus College, in Collegeville, PA.
The panelists are:
Doghramji started off this segment by asking the panelists, “In the last four or five years what have been the main breakthroughs as far as medications go? I know initially the biggest ones were disease-modifying injectables, but are there more injectables, oral, and/or IV options coming out?”
According to Coyle, “in the last five years we’ve had five new disease-modifying therapies approved for relapsing forms of MS. The most recent is pegylated interferon beta-1a, a new form of interferon beta. We have a monoclonal antibody (alemtuzumab) that has an initial 5-day cycle of treatment, one year later a 3-day cycle of treatment, and then you don’t treat again unless there’s breakthrough activity. And there are three oral agents, either pills or capsules. We have dimethyl fumarate, a twice-a-day capsule that was approved in 2013; we have teriflunomide which comes in two different doses, 7 or 14 milligrams, a daily pill; and we have fingolimod, a daily capsule, at a dose of 0.5 milligrams. Obviously these oral agents offer a non-injectable form of treatment so they were a major breakthrough.”
Lublin noted that comparative efficacy data has shown that the new oral agents are at least as effective and in some cases more effective than the therapies that preceded them. -
Click here to see more and to watch the videos